Merck's (MRK) Odanacatib Met Primary Endpoint; Company Planing NDA
Tweet Send to a Friend
Merck (NYSE: MRK) today announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE